Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nuvectis Pharma Inc (NVCT)

Nuvectis Pharma Inc (NVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,230
  • Shares Outstanding, K 17,769
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,260 K
  • 60-Month Beta 0.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.08
Trade NVCT with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.40
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -0.40
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -48.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.30 +3.17%
on 04/15/24
8.79 -26.05%
on 03/26/24
-2.39 (-26.88%)
since 03/25/24
3-Month
6.30 +3.17%
on 04/15/24
12.10 -46.28%
on 03/14/24
-1.23 (-15.91%)
since 01/25/24
52-Week
6.20 +4.84%
on 01/23/24
18.65 -65.15%
on 06/14/23
-8.10 (-55.48%)
since 04/25/23

Most Recent Stories

More News
Bump up Your Long Term Portfolio Performance With Low Beta Stocks

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 393.44 (-3.82%)
NERV : 2.48 (-1.59%)
STIX : 0.3000 (-19.14%)
SERA : 9.84 (-1.99%)
TCRX : 7.22 (-2.17%)
NVCT : 6.55 (-2.38%)
Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S....

NVCT : 6.55 (-2.38%)
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement

Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused...

NVCT : 6.55 (-2.38%)
5 Best Performing Micro-Cap Stocks Through the First Half of 2022

The first half of 2022 is finally in the books and it could not have come sooner. Major U.S. indices

^BTCUSD : 64,105.25 (+0.07%)
^BTCUSDT : 64,010.20 (-0.22%)
FEDU : 8.70 (-1.69%)
NERV : 2.48 (-1.59%)
TRVI : 2.49 (-6.04%)
NVCT : 6.55 (-2.38%)
HUSA : 1.6100 (-5.29%)
Nuvectis Pharma Announces FDA Clearance of IND for NXP800

FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of...

NVCT : 6.55 (-2.38%)
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients

FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development...

NVCT : 6.55 (-2.38%)
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference

FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of...

NVCT : 6.55 (-2.38%)
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights

Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR “New Drugs on...

NVCT : 6.55 (-2.38%)
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference

Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused...

NVCT : 6.55 (-2.38%)
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference

Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused...

NVCT : 6.55 (-2.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.

See More

Key Turning Points

3rd Resistance Point 7.30
2nd Resistance Point 7.03
1st Resistance Point 6.87
Last Price 6.55
1st Support Level 6.44
2nd Support Level 6.17
3rd Support Level 6.01

See More

52-Week High 18.65
Fibonacci 61.8% 13.89
Fibonacci 50% 12.42
Fibonacci 38.2% 10.96
Last Price 6.55
52-Week Low 6.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar